Wikipedia:ImmunityBio

ImmunityBio is a life sciences company that focuses on immunotherapy and leveraging the body’s Natural Killer cells to enhance the immune system’s response to cancer and chemotherapy.

History
ImmunityBio was founded in 2014 by Dr. Patrick Soon-Shiong.

ImmunityBio’s clinical pipeline consists of 26 actively recruiting clinical trials—17 of which are in Phase 2 or 3 development—across 13 indications in liquid and solid tumors (including bladder, pancreatic, and lung cancers) and infectious diseases (including SARS-CoV-2 and HIV). Anktiva™, ImmunityBio’s lead cytokine fusion protein, is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.

On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund trials involving non-human primates. The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."

ImmunityBio is developing several vaccine candidates against COVID-19. Their vaccines are under Phase I, II, III stage in various countries.


 * 1) Adenovirus Type 5 + DNA (hAd5)
 * 2) Nanostructured lipid carriers (NLCs) + RNA (saRNA)
 * 3) Yeast + RBD + Adjuvants